Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Collegium Pharmaceuticals Inc (COLL), Galmed Pharmaceuticals Ltd (GLMD) and Three Other Stocks Are Registering Significant Gains Today

The US stock market opened on a positive note today and maintained the momentum, following the Fed’s decision to keep interest rates unchanged.

As the main indices are heading towards ending today’s session in the green territory, let’s take a look at five stocks that are registering significant gains today. The companies in question are Collegium Pharmaceuticals Inc (NASDAQ:COLL), Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), Conatus Pharmaceuticals Inc (NASDAQ:CNAT), TerraForm Global Inc (NASDAQ:GLBL), and FormFactor Inc (NASDAQ:FORM), and in this article we are going to discuss the developments that sent these stocks through the roof today as well as assess the hedge fund sentiment towards them.

We determine hedge fund sentiment by analyzing the equity portfolios of some of the best-performing hedge funds and institutional investors. Through extensive research, we have determined that the due diligence that these investors employ, as well as their long-term focus makes them perfect targets to emulate. However, the results of our analysis have also showed that the small-cap picks of these funds can generate much better returns, with the 15 most popular small-cap stocks beating the market by an average of 95 basis points per month (see more detail here).

dna, bio, clone, helix, medical, health, research, cell, gene, microscopic, render, tech, chemistry, molecular, liquid, life, biotechnology, technology, medicine, molecule,

everything possible/

Collegium Pharmaceuticals Inc (NASDAQ:COLL)’s stock has surged by over 22%. No significant news seem to be affecting the stock, but  the stock has had a solid bull run in the last several trading session. Earlier today, Jefferies Group reaffirmed its ‘Buy’ rating on the stock, joining Needham & Company LLC, which last week reiterated its ‘Buy’ rating and $30 price target. Among the funds we track, 12 funds held $69 million worth of Collegium Pharmaceuticals’s stock at the end of June, having amassed 24.90% of its outstanding stock, compared to 12 investors that held $124 million worth of shares a quarter earlier.

Follow Collegium Pharmaceutical Inc
Trade (COLL) Now!

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s shares have spiked by around 10% on news that the company has signed an Investigator-Initiated Clinical Trial Agreement with the University of California, San Diego, School of Medicine. The study will act as Phase I/IIa trial to assess safety, tolerability, efficacy, and pharmacokinetics of Aramchol  for treating nonalcoholic fatty liver disease in a juvenile population. The number of funds from our database long Galmed Pharmaceuticals declined by one to six in the second quarter, while the total value of their holdings slid to $2.21 million from $3.28 million.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has gained around 5% extending the gains from the last couple of days prompted by Allergan’s acquisition of Tobira Therapeutics. Conatus and Tobira both are developing treatment for non-alcoholic steatohepatitis (NASH). Four hedge funds from our database have positions in Conatus Pharmaceuticals as of the end of June, having amassed  $2.652 million worth of stock, which represented  about 6% of Conatus Pharmaceuticals’ float.

Follow Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)
Trade (NASDAQ:CNAT) Now!

TerraForm Global Inc (NASDAQ:GLBL) stock is over 14% in the green today. Earlier this week the company announced that it is exploring strategic alternatives for its business, which sent its stock higher. Yesterday, Bloomberg reported that BlackRock might be considering to bid on another SunEdison yieldco, TerraForm Power Inc. (NASDAQ:TERP), which is also trading higher today. A total of 16 hedge funds we track hold about $110 million of TerraForm Global stock as of the end of June, down from 23 funds holding $81.56 million worth of stock a quarter earlier.

Follow Terraform Global Inc.
Trade (GLBL) Now!

FormFactor Inc (NASDAQ:FORM)’s stock has advanced by some 11% in Thursday session. Earlier today, Craig Hallum announced that it initiated coverage on FormFactor’s stock with a ‘Buy’ rating. A total of 14 investors from our database amassed $55.29 million worth of FormFactor Inc (NASDAQ:FORM)’s stock heading into the third quarter, which compared with 14 funds holding $40 million worth of shares a quarter earlier.

Follow Formfactor Inc (NASDAQ:FORM)
Trade (NASDAQ:FORM) Now!

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.